Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma
NCT01952769Phase 2Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Feb 2014
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pidilizumab in diffuse intrinsic pontine glioma (DIPG), sponsored by Hadassah Medical Organization. Status: unknown.
02
Drugs
pidilizumab
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT01952769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01952769.